Adamis Pharmaceuticals (NASDAQ:ADMP) and ChemoCentryx (NASDAQ:CCXI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Valuation & Earnings
This table compares Adamis Pharmaceuticals and ChemoCentryx’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Adamis Pharmaceuticals||$13.07 million||8.14||-$25.53 million||($0.90)||-2.50|
|ChemoCentryx||$82.50 million||6.68||$18.19 million||$0.36||30.31|
ChemoCentryx has higher revenue and earnings than Adamis Pharmaceuticals. Adamis Pharmaceuticals is trading at a lower price-to-earnings ratio than ChemoCentryx, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Adamis Pharmaceuticals and ChemoCentryx, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Adamis Pharmaceuticals currently has a consensus target price of $6.63, suggesting a potential upside of 194.44%. ChemoCentryx has a consensus target price of $17.10, suggesting a potential upside of 56.74%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Adamis Pharmaceuticals is more favorable than ChemoCentryx.
Risk & Volatility
Adamis Pharmaceuticals has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
This table compares Adamis Pharmaceuticals and ChemoCentryx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
22.4% of Adamis Pharmaceuticals shares are held by institutional investors. Comparatively, 53.8% of ChemoCentryx shares are held by institutional investors. 10.2% of Adamis Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of ChemoCentryx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ChemoCentryx beats Adamis Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company’s specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men’s and women’s health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
ChemoCentryx Company Profile
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for Adamis Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.